India's Sun Pharma wins South Africa approval to launch generic Ozemp…

Sun Pharmaceutical has won regulatory approval from South Africa's health authority to manufacture and sell a generic semaglutide injection, making South Africa the second market after India where the company has secured clearance for the drug. The approval arrives following Novo Nordisk's patent expiration in March and threatens to disrupt markets dominated by Novo's Ozempic/Wegovy and Eli Lilly's Mounjaro. If you're building obesity or diabetes drugs in emerging markets, the branded players just lost their price protection in South Africa - Sun Pharma is now selling semaglutide at a fraction of Ozempic's cost, and regulators are racing to regulate compounded versions rather than block them. Your window to reach patients on price before the generics own the market is closing.